IDO1 and metastatic melanoma: However, based on recent negative results of ECHO-301/KEYNOTE-252 phase 3 trial in metastatic melanoma (clinical trial information: NCT02752074) (25), many trials, particularly those that use the IDO inhibitor epacadostat, needed to be halted.